BioCryst Pharmaceuticals Inc. said Wednesday its partner Shionogi & Co. filed for approval to market BioCryst's IV flu drug peramivir in Japan. Shionogi's filing triggers a $7 million milestone payment to BioCryst. Peramivir is an intravenous drug intended to... BioCryst Pharmaceuticals - Drug - Asia - Peramivir - Society and Culture
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment